Erica Lanier
Family · Statesboro, GANPI 1588185904
Payments from drug & device makers
Across 167 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$758
- Lilly USA, LLC$414
- Novo Nordisk$328
- AstraZeneca$292
- Takeda Pharmaceuticals U.S.A., Inc.$155
- Amgen$145
- plus $861 from 22 others
What the payments were for
- Food & beverage$2,88798%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $758 |
| Lilly USA, LLC | 25 | $414 |
| Novo Nordisk | 24 | $328 |
| AstraZeneca | 16 | $292 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $155 |
| Amgen | 9 | $145 |
| Axsome Therapeutics, Inc. | 5 | $122 |
| Pfizer | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $82 |
| Novartis | 4 | $74 |
| Boehringer Ingelheim | 4 | $67 |
| Exact Sciences | 3 | $50 |
| Ardelyx, Inc. | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $37 |
| Abbott | 2 | $37 |
| GSK | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Dexcom, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Merck | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,953 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $64,538 |
| OzempicSemaglutide | 33 | $30,937 |
| JardianceEmpagliflozin | 19 | $25,557 |
| JanuviaSitagliptin Phosphate | 19 | $21,335 |
| LinzessLinaclotide | 18 | $15,478 |
| EliquisApixaban | 26 | $15,191 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $14,934 |
| MyrbetriqMirabegron | 21 | $10,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,306 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $7,863 |
| Memantine Hcl | 15 | $2,351 |
| Midodrine Hcl | 19 | $1,645 |
| Ezetimibe | 16 | $1,558 |
| Atorvastatin Calcium | 93 | $1,253 |
| Duloxetine Hcl | 34 | $1,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $414 | $64,53847 claims |
| Novo NordiskOzempic | $328 | $30,93733 claims |
| Boehringer IngelheimJardiance | $67 | $25,55719 claims |
| MerckJanuvia | $18 | $21,33519 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $30 | $18,16926 claims |
| AbbVieLinzess | $758 | $15,47818 claims |
| PfizerEliquis | $94 | $15,19126 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $10,99721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Statesboro
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.